GNFT Stock Overview
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Price-To-Earnings ratio (4x) is below the French market (15x)
Risk Analysis
No risks detected for GNFT from our risk checks.
My Notes
NewNotes are coming soon
Genfit S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.81 |
| 52 Week High | €4.77 |
| 52 Week Low | €2.80 |
| Beta | 1.03 |
| 1 Month Change | -3.98% |
| 3 Month Change | -4.99% |
| 1 Year Change | 5.72% |
| 3 Year Change | -75.58% |
| 5 Year Change | -85.18% |
| Change since IPO | -70.60% |
Recent News & Updates
We Think Genfit (EPA:GNFT) Can Manage Its Debt With Ease
Dec 28
New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)
Sep 30Recent updates
We Think Genfit (EPA:GNFT) Can Manage Its Debt With Ease
Dec 28New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)
Sep 30Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term
Jun 29Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.
Mar 14Is Genfit (EPA:GNFT) A Risky Investment?
Nov 28
Shareholder Returns
| GNFT | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 0.4% | -1.7% | 1.4% |
| 1Y | 5.7% | -41.0% | 2.8% |
Return vs Industry: GNFT exceeded the French Biotechs industry which returned -41% over the past year.
Return vs Market: GNFT exceeded the French Market which returned 2.8% over the past year.
Price Volatility
| GNFT volatility | |
|---|---|
| GNFT Average Weekly Movement | 4.0% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.8% |
| 10% least volatile stocks in FR Market | 2.4% |
Stable Share Price: GNFT is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: GNFT's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 134 | M. Prigent | https://www.genfit.com |
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company’s products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure.
Genfit S.A. Fundamentals Summary
| GNFT fundamental statistics | |
|---|---|
| Market Cap | €189.19m |
| Earnings (TTM) | €47.80m |
| Revenue (TTM) | €94.24m |
4.0x
P/E Ratio2.0x
P/S RatioIs GNFT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GNFT income statement (TTM) | |
|---|---|
| Revenue | €94.24m |
| Cost of Revenue | €0 |
| Gross Profit | €94.24m |
| Other Expenses | €46.44m |
| Earnings | €47.80m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Apr 13, 2023
| Earnings per share (EPS) | 0.96 |
| Gross Margin | 100.00% |
| Net Profit Margin | 50.72% |
| Debt/Equity Ratio | 62.2% |
How did GNFT perform over the long term?
See historical performance and comparison